

## Supplementary material

**Supplementary Table 1** Included studies and relevant information

First author [ref.]	PMID	Publication date	Type of study
Gao <i>et al</i> [13]	32899097	2020	Case Report
Yamagata <i>et al</i> [14]	30890174	2019	Case Report
Rojas <i>et al</i> [1]	29850384	2019	Case Report
Vailas <i>et al</i> [15]	31255175	2019	Case Report
Gonzalez-Sanchez <i>et al</i> [2]	28469507	2017	Case Report
Chang <i>et al</i> [16]	27433399	2016	Case Report
Gao <i>et al</i> [17]	26464735	2015	Case Report
Hwang <i>et al</i> [9]	25289093	2014	Case Report
Wang <i>et al</i> [18]	24944669	2014	Case Report
Chen <i>et al</i> [11]	27478431	2016	Case Series
Wakabayashi <i>et al</i> [19]	24765539	2014	Case Report
Gulcicek <i>et al</i> [20]	27528817	2016	Case Report
Patnayak <i>et al</i> [21]	27512553	2016	Case Report
Modi <i>et al</i> [22]	26838004	2015	Case Report
Waagner <i>et al</i> [23]	26185704	2015	Case Report
Wu <i>et al</i> [24]	26181433	2015	Case Report
Mardi <i>et al</i> [25]	24455626	2013	Case Report
Little <i>et al</i> [26]	23709554	2013	Case Report
Tokuhara <i>et al</i> [27]	22350299	2012	Case Report
Karaca <i>et al</i> [32]	21166967	2010	Case Report
Callacondo <i>et al</i> [28]	19467693	2009	Case Report
Choi <i>et al</i> [29]	17443414	2007	Case Report
Yildirim <i>et al</i> [30]	16459645	2005	Case Report
Hara <i>et al</i> [31]	15065010	2004	Case Report

**Supplementary Table 2** Data on the utilized chemotherapy and radiotherapy regimens

First author [ref.]	Neoadjuvant chemotherapy	Adjuvant chemotherapy	Adjuvant radiation therapy dosing
Gao <i>et al</i> [13]	None	None	None
Yamagata <i>et al</i> [14]	None	S-1	None
Rojas <i>et al</i> [1]	None	5-fluorouracil	None
Vailas <i>et al</i> [15]	None	paclitaxel/carbopaltin	None
Gonzalez-Sanchez <i>et al</i> [2]	None	n/a	None
Chang <i>et al</i> [16]	None	5-fluorouracil/cisplatin	None
Gao <i>et al</i> [17]	None	cisplatin/docetaxel	None
Hwang <i>et al</i> [9]	None	5-fluorouracil/cisplatin	None
Wang <i>et al</i> [18]	None	cisplatin/docetaxel	None
Chen <i>et al</i> [11]	None	None (n=8) Cisplatin-based or 5-fluorouracil-based (n=7)	50.4 Gy in 28 fractions (n=1)
Wakabayashi <i>et al</i> [19]	None	None	None
Gulcicek <i>et al</i> [20]	None	cisplatin/capecitabine	45 Gy in 25 fractions
Patnayak <i>et al</i> [21]	None	None	None
Modi <i>et al</i> [22]	carboplatin/paclitaxel	n/a	None
Waagner <i>et al</i> [23]	None	capecitabine/oxaliplatin	n/a
Wu <i>et al</i> [24]	None	5-fluorouracil/oxaliplatin	None
Mardi <i>et al</i> [25]	None	n/a	None
Little <i>et al</i> [26]	None	n/a	None
Tokuhara <i>et al</i> [27]	None	5-fluorouracil/cisplatin	None
Karaca <i>et al</i> [32]	None	None	None
Callacondo <i>et al</i> [28]	None	None	None
Choi <i>et al</i> [29]	None	5-fluorouracil/etoposide/cisplatin	None
Yildirim <i>et al</i> [30]	None	5-fluorouracil/cisplatin	None
Hara <i>et al</i> [31]	None	n/a	None